Corinne Blanchet, MS, serves as Executive Director of Program Delivery for Rare Disease & Pediatrics at Premier Research, bringing over 26 years of comprehensive experience in clinical research leadership. With a strong foundation in project management, Ms. Blanchet oversees the successful delivery of complex therapeutic programs, ensuring a focus on patient engagement, on-time delivery, and compliance with industry standards. Ms. Blanchet's career includes pivotal operational roles at global CROs. She excels at delivering operational strategy that mitigates risk while driving cross-functional collaboration.
Ms. Blanchet holds a DESS in Biology and Pharmacology of Ageing from the University of Marne-La-Vallée, France (1997), a Masters in Biochemistry from the University of Science - Jussieu (Paris VI) (1996), and is a Certified Clinical Research Associate from the University of St Antoine (Paris VI). Her educational background complements her strategic leadership in advancing clinical research and pharmacology.
The FDA's diversity guidance for clinical trials marks a significant step towards equity in medical research. This presentation will help us to understand its impact on sponsors, patients, and advocacy groups. Sponsors must now adopt inclusive trial designs and recruitment strategies, while patients gain improved access to tailored treatments, fostering trust. Advocacy groups play a pivotal role in raising awareness and engagement among underrepresented communities. In the context of rare disease trials, where identifying patients is exceptionally challenging, striking a balance between inclusivity and sufficient enrollment is crucial. This presentation will explore the potential of FDA diversity guidelines across medical research stakeholders, addressing the nuanced challenges of patient identification and trial participation in rare disease research